ACTH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-22. Numbers and descriptions here follow the published literature rather than marketing material.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Contains one methionine sulfur atom |
| Molecular mass | Approximately 814 Da | Consistent with a seven-residue peptide |
| Appearance | White to off-white powder | Typical lyophilized form |
| Solubility | Freely soluble in water | Also soluble in dimethyl sulfoxide |
| Typical storage | -20 °C, desiccated | Limits methionine oxidation |
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
In the use of the terms "tranquilizer" and "ataractic", medical practitioners distinguished between the "major tranquilizers" or "major ataractics", which referred to drugs used to treat psychoses, and the "minor tranquilizers" or "minor ataractics", which referred to drugs used to treat neuroses. While popular during the 1950s, these terms are infrequently used today. They are being abandoned in favor of "antipsychotic", which refers to the drug's desired effects. Today, "minor tranquilizer" can refer to anxiolytic and/or hypnotic drugs such as the benzodiazepines and nonbenzodiazepines, which are useful as generally short-term management for insomnia together with cognitive behavioral therapy for insomnia. They are potentially addictive sedatives. Antipsychotics are broadly divided into two groups, the typical or first-generation antipsychotics and the atypical or second-generation antipsychotics. The difference between first- and second-generation antipsychotics is a subject of debate. The second-generation antipsychotics are generally distinguishable by the presence of 5HT2A receptor antagonism and a corresponding lower propensity for extrapyramidal side effects compared to first-generation antipsychotics.
== Epidemiology == ALD has not been shown to have an increased incidence in any specific country or ethnic group. In the United States, the incidence of affected males is estimated at 1:21,000. Overall incidence of hemizygous males and carrier females is estimated at 1:16,800. The reported incidence in France is estimated at 1:22,000.
They cited concerns over deviations from standard acquisition processes and a dome subscription model that could "give Musk undue influence over national security." Another key conflict of interest involves four-star general Terrence J. O'Shaughnessy, former head of U.S. homeland missile defense, who now reports directly to Musk at SpaceX. Michael D. Griffin, founder of the Space Development Agency behind the Golden Dome, has also faced scrutiny. After traveling to Russia with a young Musk in 2001 to study ICBMs, Griffin steered $2 billion in NASA contracts to Musk's newfound space company. SpaceX has since secured missile-tracking satellite contracts through Griffin's SDA as part of its Starshield program. Griffin also serves as an advisor to Castelion, a startup founded by former SpaceX executives that seeks to mass-produce hypersonic weapons. General Michael A. Guetlein of the U.S. Space Force, was nominated to run the program in June 2025, was confirmed by the Senate the following month, and assumed the position on July 21, 2025. Dr. Douglas Matty was named to head the project in January 2026. Republicans included $25 billion for the Golden Dome in their 2025 reconciliation spending bill. The fiscal 2026 defense appropriations bill, passed by Congress on February 3, 2026, included $13.4 billion for space and missile defense systems for the Golden Dome. As of December 2025, the U.S.
LC/MS Preprocessing: SIRIUS can automatically detect and align chromatographic features across multiple samples, including adduct assignment. The preprocessing further provides quality metrics that enable users to prioritize and filter results for downstream analysis. Spectral Library (Analog) Search: SIRIUS enables rapid identity search and analog search against spectral libraries. An identity search matches the query spectrum against library spectra sharing the same precursor mass. Conversely, an analog search matches against library spectra with different precursor masses. These spectral library hits are auxiliary annotations alongside the CSI:FingerID results and do not influence the ranking of structure candidates. Substructure Annotations: Substructure annotations serve as a visualization tool to illustrate the connection between the input MS/MS spectrum, the predicted CSI:FingerID structure candidates, and any (analog) spectral library matches. This feature is based on the combinatorial fragmentation of the candidate structure and operates independently of the scoring algorithm CSI:FingerID uses to rank structure candidates. Structure Sketcher: The Structure Sketcher is a user interface component that enables manual modification of existing candidate structures or the creation of new ones. Users can integrate these manually-defined structures into the list of candidates for subsequent analysis.
Sources: en.wikipedia.org
7 November – Scottish ministers say they will not comply with UK government legislation to enforce a 40% minimum service during strike action, with Neil Gray, the Cabinet Secretary for Wellbeing Economy, Fair Work and Energy, describing the plans, outlined in the Strikes (Minimum Service Levels) Act, as "appalling". 9 November – First Minister Humza Yousaf defends £11,000 worth of roaming charges accrued Health Secretary Michael Matheson as he used his parliamentary iPad during a holiday to Morocco as a "legitimate parliamentary expense". Matheson has blamed the charges on an "outdated sim card". 10 November – Around 500 employees of Scottish Water belonging to the GMB, Unite and Unison trade unions, begin a four-day strike over a pay dispute. Scotland's Health Secretary, Michael Matheson, agrees to pay back the £11,000 of roaming charges he built up while using his iPad during a holiday in Morocco. 11 November – Edinburgh will become the first city in Scotland to make pavement parking illegal, starting in January 2024. 12 November – NHS Greater Glasgow and Clyde, Scotland's largest health board, is named in a corporate homicide investigation following the deaths of four patients at a Glasgow hospital. 14 November – Seven members of a paedophile gang are found guilty of running a child sex abuse ring in Glasgow, described by the NSPCC as one of the worst cases of its kind in decades. Scottish Conservatives threaten to table a vote of no confidence in Health Secretary Michael Matheson if he refuses to hand over his ministerial iPad.
Many of the characteristics of micelles differ from those of bulk solvents. For example, the micelles are, by nature, spatially heterogeneous with a hydrocarbon, nearly anhydrous core and a highly solvated, polar head group. They have a high surface-to-volume ratio due to their small size and generally spherical shape. Their surrounding environment (pH, ionic strength, buffer ion, presence of a co-solvent, and temperature) has an influence on their size, shape, critical micelle concentration, aggregation number and other properties. Another important property of micelles is the Krafft point, the temperature at which the solubility of the surfactant is equal to its CMC. For HPLC applications involving micelles, it is best to choose a surfactant with a low Krafft point and CMC. A high CMC would require a high concentration of surfactant which would increase the viscosity of the mobile phase, an undesirable condition. Additionally, a Krafft point should be well below room temperature to avoid having to apply heat to the mobile phase. To avoid potential interference with absorption detectors, a surfactant should also have a small molar absorptivity at the chosen wavelength of analysis. Light scattering should not be a concern due to the small size, a few nanometers, of the micelle. The effect of organic additives on micellar properties is another important consideration. A small amount of organic solvent is often added to the mobile phase to help improve efficiency and to improve separations of compounds. Care needs to be taken when determining how much organic to add.
In 1896, Viennese dermatologist Leopold Freund (1868-1943) used X-rays to treat patients for the first time. He successfully irradiated the hairy nevus of a young girl. In 1897, Hermann Gocht (1869–1931) published the treatment of trigeminal neuralgia with X-rays, and Alexei Petrovich Sokolov (1854-1928) wrote about radiotherapy for arthritis in the oldest radiology journal, Advances in the field of X-rays (RöFo). In 1922, X-rays were recommended as safe for many diseases and for diagnostic purposes. Radiation protection was limited to recommending doses that would not cause erythema (reddening of the skin). For example, X-rays were promoted as an alternative to tonsillectomy. It was also boasted that in 80% of cases of diphtheria carriers, Corynebacterium diphtheriae was no longer detectable within two to four days. In the 1930s, Günther von Pannewitz (1900–1966), a radiologist from Freiburg, Germany, perfected what he called X-ray stimulation radiation for degenerative diseases. Low-dose radiation reduces the inflammatory response of tissues. Until about 1960, children with diseases such as ankylosing spondylitis or favus (head fungus) were irradiated, which was effective but led to increased cancer rates among patients decades later. In 1926, the American pathologist James Ewing (1866-1943) was the first to observe bone changes as a result of radiotherapy, which he described as radiation osteitis (now Osteoradionecrosis). In 1983, Robert E. Marx stated that osteoradionecrosis is radiation-induced aseptic bone necrosis.
=== Venture capital legacy === HVEC was among the first three investments of ARD, the first modern venture capital fund. By 1960, it was ARD's largest and most successful asset, having grown the original $200,000 investment to $13.2 million. These returns sustained ARD through its early years and enabled its 1957 investment in Digital Equipment Corporation. The latter's eventual $355 million return established the now-standard model where exceptional returns from a single investment justify a venture fund's diversified portfolio of high-risk bets. The company also embodied ARD's innovative methods of investing: active participation in management, selection for scientific talent, and focus on technology-intensive industries where technical barriers provided durable profitability. Barron's described HVEC as "an ideal example of the way [ARD] likes to work."
The U.S. Food and Drug Administration noted in 2007 that fruit and vegetable-related outbreaks of food poisoning are on the rise and had struck in spinach, tomatoes, lettuce and cantaloupes. The agency urged fruit and vegetable processors to adopt food safety plans similar to those in the meat industry. An outbreak of Salmonella Saintpaul in 2008 was characterized by the US Center for Disease Control as the largest foodborne outbreak in a decade. Some 1304 infected persons were identified in 43 states, at least 252 were hospitalized and two deaths were possibly linked to the outbreak. CDC noted that the trace back of fresh produce, such as tomatoes, through the supply chain could be very difficult and labor-intensive. Ironically, the carrier item was ultimately determined to be jalapeño peppers, not tomatoes.
Sources: en.wikipedia.org
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.
Most published work uses intranasal administration, matching the route of the registered Russian formulation. Some animal experiments use intravenous or intraperitoneal injection. The route matters because the intact peptide is cleared rapidly from blood, so exposure differs between methods.
A purity value describes the share of the powder accounted for by the target peptide, usually by high-performance liquid chromatography. It does not confirm that the sequence is correct, which requires mass spectrometry or amino acid analysis. Purity and identity are separate checks.
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.